scholarly journals Hsp110 mitigates α-synuclein pathology in vivo

2019 ◽  
Vol 116 (48) ◽  
pp. 24310-24316 ◽  
Author(s):  
Yumiko V. Taguchi ◽  
Erica L. Gorenberg ◽  
Maria Nagy ◽  
Drake Thrasher ◽  
Wayne A. Fenton ◽  
...  

Parkinson’s disease is characterized by the aggregation of the presynaptic protein α-synuclein and its deposition into pathologic Lewy bodies. While extensive research has been carried out on mediators of α-synuclein aggregation, molecular facilitators of α-synuclein disaggregation are still generally unknown. We investigated the role of molecular chaperones in both preventing and disaggregating α-synuclein oligomers and fibrils, with a focus on the mammalian disaggregase complex. Here, we show that overexpression of the chaperone Hsp110 is sufficient to reduce α-synuclein aggregation in a mammalian cell culture model. Additionally, we demonstrate that Hsp110 effectively mitigates α-synuclein pathology in vivo through the characterization of transgenic Hsp110 and double-transgenic α-synuclein/Hsp110 mouse models. Unbiased analysis of the synaptic proteome of these mice revealed that overexpression of Hsp110 can override the protein changes driven by the α-synuclein transgene. Furthermore, overexpression of Hsp110 is sufficient to prevent endogenous α-synuclein templating and spread following injection of aggregated α-synuclein seeds into brain, supporting a role for Hsp110 in the prevention and/or disaggregation of α-synuclein pathology.

Author(s):  
Genilso Gava-Junior ◽  
Cláudio Roque ◽  
Julieta Mendes-Oliveira ◽  
Ana C Bernardino ◽  
Inês Serrenho ◽  
...  

2019 ◽  
Vol 10 (2) ◽  
pp. 602-615 ◽  
Author(s):  
Sumita Elendran ◽  
Saravanan Muniyandy ◽  
Wang Wang Lee ◽  
Uma D. Palanisamy

Geraniin and its metabolites, found in many edibles, were classified as per the BCS. This finding can be used to predict its' in vivo oral absorption.


Il Farmaco ◽  
1999 ◽  
Vol 54 (9) ◽  
pp. 594-599 ◽  
Author(s):  
Elia Biganzoli ◽  
Luigi A Cavenaghi ◽  
Roberta Rossi ◽  
Maria C Brunati ◽  
Maria L Nolli

mSphere ◽  
2015 ◽  
Vol 1 (1) ◽  
Author(s):  
Coyne G. Drummond ◽  
Cheryl A. Nickerson ◽  
Carolyn B. Coyne

ABSTRACT Coxsackievirus B (CVB), a member of the enterovirus family of RNA viruses, is associated with meningitis, pericarditis, diabetes, dilated cardiomyopathy, and myocarditis, among other pathologies. CVB is transmitted via the fecal-oral route and encounters the epithelium lining the gastrointestinal tract early in infection. The lack of suitable in vivo and in vitro models to study CVB infection of the gastrointestinal epithelium has limited our understanding of the events that surround infection of these specialized cells. Here, we report on the development of a three-dimensional (3-D) organotypic cell culture model of human intestinal epithelial cells that better models the gastrointestinal epithelium in vivo. By applying this 3-D model, which recapitulates many aspects of the gastrointestinal epithelium in vivo, to the study of CVB infection, our work provides a new cell system to model the mechanisms by which CVB infects the intestinal epithelium, which may have a profound impact on CVB pathogenesis. Despite serving as the primary entry portal for coxsackievirus B (CVB), little is known about CVB infection of the intestinal epithelium, owing at least in part to the lack of suitable in vivo models and the inability of cultured cells to recapitulate the complexity and structure associated with the gastrointestinal (GI) tract. Here, we report on the development of a three-dimensional (3-D) organotypic cell culture model of Caco-2 cells to model CVB infection of the gastrointestinal epithelium. We show that Caco-2 cells grown in 3-D using the rotating wall vessel (RWV) bioreactor recapitulate many of the properties of the intestinal epithelium, including the formation of well-developed tight junctions, apical-basolateral polarity, brush borders, and multicellular complexity. In addition, transcriptome analyses using transcriptome sequencing (RNA-Seq) revealed the induction of a number of genes associated with intestinal epithelial differentiation and/or intestinal processes in vivo when Caco-2 cells were cultured in 3-D. Applying this model to CVB infection, we found that although the levels of intracellular virus production were similar in two-dimensional (2-D) and 3-D Caco-2 cell cultures, the release of infectious CVB was enhanced in 3-D cultures at early stages of infection. Unlike CVB, the replication of poliovirus (PV) was significantly reduced in 3-D Caco-2 cell cultures. Collectively, our studies show that Caco-2 cells grown in 3-D using the RWV bioreactor provide a cell culture model that structurally and transcriptionally represents key aspects of cells in the human GI tract and can thus be used to expand our understanding of enterovirus-host interactions in intestinal epithelial cells. IMPORTANCE Coxsackievirus B (CVB), a member of the enterovirus family of RNA viruses, is associated with meningitis, pericarditis, diabetes, dilated cardiomyopathy, and myocarditis, among other pathologies. CVB is transmitted via the fecal-oral route and encounters the epithelium lining the gastrointestinal tract early in infection. The lack of suitable in vivo and in vitro models to study CVB infection of the gastrointestinal epithelium has limited our understanding of the events that surround infection of these specialized cells. Here, we report on the development of a three-dimensional (3-D) organotypic cell culture model of human intestinal epithelial cells that better models the gastrointestinal epithelium in vivo. By applying this 3-D model, which recapitulates many aspects of the gastrointestinal epithelium in vivo, to the study of CVB infection, our work provides a new cell system to model the mechanisms by which CVB infects the intestinal epithelium, which may have a profound impact on CVB pathogenesis. Podcast: A podcast concerning this article is available.


2002 ◽  
Vol 64 (3) ◽  
pp. 413-424 ◽  
Author(s):  
Robert H Pierce ◽  
Christopher C Franklin ◽  
Jean S Campbell ◽  
Robert P Tonge ◽  
Weichao Chen ◽  
...  

2012 ◽  
Vol 315 (2) ◽  
pp. 178-188 ◽  
Author(s):  
Hannah van Malenstein ◽  
Chris Verslype ◽  
Petra Windmolders ◽  
Rudy van Eijsden ◽  
Frederik Nevens ◽  
...  

2021 ◽  
Author(s):  
Ashok Chakraborty ◽  
Anil Diwan ◽  
Vijetha Chiniga ◽  
Vinod Arora ◽  
Preetam Holkar ◽  
...  

Remdesivir (RDV) is the only antiviral drug so far approved for COVID-19 therapy by the FDA. However its efficacy is limited in vivo due to its low stability in presence of plasma. This paper compared the stability of RDV encapsulated with our platform technology based polymer NV-387 (NV-CoV-2), in presence of plasma in vitro and in vivo . Furthermore, a non-clinical pharmacology studies of NV-CoV-2 (Polymer) and NV-CoV-2-R (Polymer encapsulated Remdesivir ) in both NL-63 infected and uninfected rats were done. In an in vitro cell culture model experiment, antiviral activity of NV-CoV-2 and NV-CoV-2-R are also compared with RDV.


Sign in / Sign up

Export Citation Format

Share Document